Alkermes plc – A Global Biopharmaceutical Company

About Us

About Alkermes

Our Company Message From the CEO

Leadership

Management Team Board of Directors

Collaborations

Strategic Partners

Other Information

Locations

Products

Our Products

Products Overview

Key Products

United States European Union

Research & Development

R&D Overview Our R&D Approach Pipeline Technology Platforms Manufacturing

Other Information

Clinical Trials Investigator Initiated Trials Medical Education Grants

Contract Services

Why Work With Us? Our Promise to Our Partners Our Partners

Capabilities

Capabilities Overview Range of Services Publications

Investors

Corporate Overview Press Releases Investor Events Stock Information SEC Filings Annual Reports

Financials

Snapshot Trading Statistics

Other Information

Email Alerts

News & Events

Press Releases Company Events Media Kit

Careers

Working At Alkermes Meet Alkermes Employees Search Jobs Benefits Employee FAQs

Latest News

Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer’s Agitation, Depression and Other CNS Diseases Read More
Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 35th Annual Health Care Conference Read More
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2014 and Provides Financial Expectations for 2015 Read More